Objectives:The study evaluated the 10-year healthcare-associated infections (HCAI) data in the pediatric cardiovascular surgery intensive care unit (PCVS-ICU). Methods: The electronic data of 106 patients with HCAI between 2012 and 2021 were retrospectively analyzed for the infection sites, isolated microorganisms, and antibiotic resistance. Results: 3617 patients with 29155 patient days in our 12-bedded PCVS-ICU were evaluated. There were 64 HCAIs during 2012-2016, comprised of 17 (26.5%) bloodstream infections (BSI), 16 (25%) pneumonia, 13 (20.3%) urinary tract infections (UTI), 8 (12.5%) ventilator-associated pneumonia (VAP), 7 (11.1%) surgical site infection (SSI), and 3 (4.6%) soft-tissue infection (STI). In contrast, 42 HCAIs were observed in 2017-2021, which included 17 (40.4%) BSI, 10 (23.8%) pneumonia, 7 (16.6%) VIP, 4 (9.6%) UTI, 3 (7.2%) SSI, and 1 (2.4%) STI. The most common pathogen was the Candida species. The ventilator usage rate was 2.8 per 8635 ventilator days and 0.42 per 6439 ventilator days in the first and second five years, respectively. The rate of central venous catheter (CVC) use was 2.04 and 0.96 in the first and second five years, respectively. Conclusion:The most common HCAI was BSI, and the most common isolated pathogen was Candida species within ten years in our PCVS-ICU. The infection rate, CVC, and UC usage rates were decreased, with an increased compliance rate on hand hygiene in the second five years, indicating strict adherence to infection control measures.
Introduction: Fosfomycin has started to be used again as a possible therapeutic alternative in cases injected with resistant bacterial pathogens. Its primary mechanism of action is inhibition of the first step of cell wall synthesis; This mechanism is effective against both Gram-positive and Gram- negative bacterial groups. However, its clinical efficacy against bacteria that develop multidrug resistance is largely unknown. Therefore, we aimed to evaluate the clinical and microbiological efficacy of intravenous Fosfomycin in a tertiary care center. Methods: The group of adult patients aged 18 years and over who applied to the hospital between January 2018 and December 2022 and were given intravenous fosfomycin therapy for at least 24 hours due to any infection were retrospectively analyzed. Results: 71 patients were included in our study. The female/male ratio of these patients was 35/36, and the mean age was 61.5±17.0 (18-84). The avarage time to treatment was 10.6 days (11.3-+11.4). 22 patients (31%) from Intensive Care Unit and 49 (69%) patients from other clinics were included in the study. 18 bacteremia (26%), 15 pneumonia (21%), 14 wound infections (19%), 13 ventilator-associated pneumonia (18%), 5 urinary tract infections (UTI) (8%), 4 abdominal infections (6%) and 2 endocarditis (3%). Detected causative microorganisms were 18 carbapenem susceptible Klebsiella pneumoniae (44%), pandrug resistan Klebsiella pneumoniae (17.5%), 5 MRSA (12.5%), 5 pandrug resistan Pseudomonas aerinosa (12%) ,4 Escherichia coli (10%), 1 Acinetobacterbaumanii (2.5%) and 1 Enterobacter spp. (2.5%). Looking at the underlying diseases, one of our patients had diabetes mellitus and another patient had chronic renal failure. Mean procalcitonin (PCT) and C reaktive protein (CRP) (cutoff value0.5 ng/mL) values were 2.53±1.2 ng/ml and 89.7±21.9 mg/dl, respectively. Median sodium (Na), potassium (K), AST, ALT, and creatinine values of the patients before and after fosfomycin IV treatment were calculated and there was no statistically significant difference. Clinics combined with fosfomycin IV were as follows: 31 meropenem (44%), 15 colistin (26%), 18 tigecycline (26%), 3 vancomycin (4%), 3 amikacin (4%) and 1 daptomycin (1%). Conclusions: According to the results of our study, it was seen that Fosfomycin is a safe and effective option in the treatment of multidrug-resistant infections. Accordingly, our results are compatible with the literature.
Background: This study aims to evaluate the etiology and outcomes of donor-derived bacterial infections in patients undergoing lung transplantation. Methods: Between January 2013 and December 2017, a total of 71 lung transplant recipients (56 males, 15 females; median age: 43.3 years) were retrospectively analyzed. The diagnosis of donor-derived bacterial infection was defined as the isolation of the same bacteria with the same antibiotic susceptibility patterns in a lung sample of donor and in one sample obtained from patients after transplantation and the presence of clinical evidence of infection. Results: Ten (14%) patients were found to have donor-derived bacterial infection. Acinetobacter baumannii was found in three, Pseudomonas aeruginosa in three, Klebsiella pneumoniae in one, Enterobacter cloacae in one, Staphylococcus aureus in one, and both Klebsiella pneumoniae and Acinetobacter baumannii in one patient. Twenty-four of lung-transplant recipients and four patients with donor-derived infection died. Conclusion: Lung transplants are usually performed in hospitalized patients or in those admitted to the intensive care unit. These patients commonly experience infection and colonization with resistant microorganisms.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.